Skip to main content

$0.091 0.002 (2.25%)

High

$0.10

Low

$0.09

Trades

2,797

Turnover

$4,713,392

Volume

50,159,971
30 June 2023 at 4:59pm
Register to track IMU and receive email alerts.

Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA

StockBot

416,823 posts

IMU released this announcement to the ASX on 2 November 2020, 8:51. The announcement is marked as price sensitive, and is 2 page(s) in length and 111.65kb in size.

You can view all announcements from IMU and see how they appear on a price chart on the announcements page.

At the date of this announcement, IMU was 0.100% short sold according to ASIC data. It was ranked the 416th most shorted stock on the ASX. It is now ranked as the 41st most shorted stock on the ASX with 5.254% of total shares short sold as of the latest reported data (19 June 2025).

Other Recent Announcements from IMU
Change of Director's Interest Notice 30 June 2023, 16:33
HER-Vaxx induced antibodies correlated with tumour reduction 30 June 2023, 8:40
Imugene PD1-Vaxx patent extended to 2040 29 June 2023, 8:39
Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA 2 November 2020, 8:51
Appendix 4C - quarterly 27 October 2020, 9:47
Appendix 2A 22 October 2020, 18:50
Proposed issue of Securities - IMU 22 October 2020, 18:43
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track IMU and receive email alerts.